A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

NCT03336333 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

590

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: Zanubrutinib
DRUG: Bendamustine
DRUG: Rituximab
DRUG: Venetoclax

Sponsor

BeiGene